The Department of Science and Technology (DOST) is set to conduct clinical trials on mixing coronavirus vaccine brands to address concerns on supply and to find out if some combination will increase immune response among participants.
The trials willl need 3,000 participants 18 years old and above, and belonging to the A1 to A4 categories of the Government’s priority list for the vaccine program.
MANILA – The country is in search of at least 3,000 individuals who wish to participte in studies on the use of mixed brands of coronavirus vaccines and booster shots.
The requirements are: individuals must be 18 years old and above and belonging to the Government’s priority list from the A1 to A4 categories in the vaccine program according to the DOST.
The clinical trials aim to address concerns on vaccine supply, says Rowena Cristina Guevara, DOST Undersecretary. The conduct of the trial will not reduce or waste vaccine supply as the participants belong to the Government’s priority list, she says.
The clinical trials will cover 12 experiments where 250 participants will be assigned to each. The trials will mix vaccine administration where first and second doses are from one brand and the booster shot is of a different brand.
According to DOST, these experiments are needed to determine which combination increases the immune response of the participants.
“We are going to look at the efficacy. Would there be improvements (if different brands are used), or would you just get the same result (or efficacy),” the DOST official says.
Similar studies are being conducted abroad, she says, they want to see its efficiency on Filipinos. She says five brands that will be used in the clinical trials: Sinovac, AstraZeneca, Pfizer, Moderna, and Sputnik V.
“This June will be the application for FDA (Food and Drug Administration) clearance to conduct the clinical trial, and (getting) the Ethics Review Board clearance,” says Undersecretary Guevara.
The study is scheduled to start July. (LO/The MiNT)